Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A T-cell re-directing bi-specific biologic composed of a modified form of human T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) human melanoma-associated antigen A4 (MAGE-A4) and fused to an anti-CD3 single-chain variable fragment (scFv), with potential antineoplastic activity. Upon intravenous administration of IMC-C103C, the TCR moiety of this agent targets and binds to MAGE-A4 on tumor cells and the anti-CD3 scFv moiety binds to CD3- expressing T-lymphocytes. This selectively cross-links tumor cells and T-lymphocytes and results in a CTL-mediated death of MAGE-A4-expressing tumor cells. MAGE-A4 is overexpressed by a variety of cancer cell types.

**Synonyms:** - IMC C103C - IMC-C103C - IMCC103C - ImmTAC IMC-C103C - ImmTAC Molecule IMC-C103C - Immune Mobilizing Monoclonal TCR Against Cancer IMC-C103C - T-cell Redirecting Bi-specific Biologic IMC-C103C